Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida. Show more
Location: 1111 Lincoln Road, Miami Beach, FL, 33139, United States | Website: https://www.pasithea.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
6.355M
52 Wk Range
$0.65 - $7.50
Previous Close
$0.85
Open
$0.81
Volume
159,256
Day Range
$0.77 - $0.83
Enterprise Value
-5.621M
Cash
7.217M
Avg Qtr Burn
-3.122M
Insider Ownership
3.26%
Institutional Own.
10.95%
Qtr Updated
06/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
PAS-004 Details Advanced cancer | Phase 1 Data readout |